Is FBRX or WHWK more profitable?

Whitehawk Therapeutics' return on equity of -79.63% beat Forte Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Forte Biosciences N/A -106.17% -85.50% Whitehawk Therapeutics N/A -79.63% -74.01%

Does the media favor FBRX or WHWK?

In the previous week, Forte Biosciences had 9 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 11 mentions for Forte Biosciences and 2 mentions for Whitehawk Therapeutics. Whitehawk Therapeutics' average media sentiment score of 1.89 beat Forte Biosciences' score of 0.63 indicating that Whitehawk Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Forte Biosciences 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Whitehawk Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer WHWK or ACRS?

In the previous week, Aclaris Therapeutics had 3 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 5 mentions for Aclaris Therapeutics and 2 mentions for Whitehawk Therapeutics. Whitehawk Therapeutics' average media sentiment score of 1.89 beat Aclaris Therapeutics' score of 1.02 indicating that Whitehawk Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Whitehawk Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Aclaris Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is WHWK or MNPR more profitable?

Monopar Therapeutics' return on equity of -12.84% beat Whitehawk Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Whitehawk Therapeutics N/A -79.63% -74.01% Monopar Therapeutics N/A -12.84% -12.57%

Does the media refer more to WHWK or MNPR?

In the previous week, Monopar Therapeutics had 13 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 15 mentions for Monopar Therapeutics and 2 mentions for Whitehawk Therapeutics. Whitehawk Therapeutics' average media sentiment score of 1.89 beat Monopar Therapeutics' score of 0.92 indicating that Whitehawk Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Whitehawk Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Monopar Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CADL or WHWK more profitable?

Candel Therapeutics' return on equity of -60.42% beat Whitehawk Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Candel Therapeutics N/A -60.42% -41.33% Whitehawk Therapeutics N/A -79.63% -74.01%

Does the media favor CADL or WHWK?

In the previous week, Candel Therapeutics and Candel Therapeutics both had 2 articles in the media. Whitehawk Therapeutics' average media sentiment score of 1.89 beat Candel Therapeutics' score of 0.71 indicating that Whitehawk Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Candel Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Whitehawk Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is WHWK or DSGN more profitable?

Design Therapeutics' return on equity of -33.07% beat Whitehawk Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Whitehawk Therapeutics N/A -79.63% -74.01% Design Therapeutics N/A -33.07% -31.29%

Does the media prefer WHWK or DSGN?

In the previous week, Whitehawk Therapeutics and Whitehawk Therapeutics both had 2 articles in the media. Whitehawk Therapeutics' average media sentiment score of 1.89 beat Design Therapeutics' score of 0.97 indicating that Whitehawk Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Whitehawk Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Design Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Whitehawk Therapeutics (WHWK) Competitors

$3.71 -0.12 (-3.13%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$3.72 +0.00 (+0.13%)

As of 07/24/2026 07:34 PM Eastern

Compare

WHWK vs. FBRX, ACRS, MNPR, CADL, and DSGN

Should you buy Whitehawk Therapeutics stock or one of its competitors? MarketBeat compares Whitehawk Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Whitehawk Therapeutics include Forte Biosciences (FBRX), Aclaris Therapeutics (ACRS), Monopar Therapeutics (MNPR), Candel Therapeutics (CADL), and Design Therapeutics (DSGN). These companies are all part of the "pharmaceutical products" industry.

How does Whitehawk Therapeutics compare to Forte Biosciences?

Forte Biosciences (NASDAQ:FBRX) and Whitehawk Therapeutics (NASDAQ:WHWK) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

In the previous week, Forte Biosciences had 9 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 11 mentions for Forte Biosciences and 2 mentions for Whitehawk Therapeutics. Whitehawk Therapeutics' average media sentiment score of 1.89 beat Forte Biosciences' score of 0.63 indicating that Whitehawk Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Forte Biosciences	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Whitehawk Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Forte Biosciences has a beta of 2.85, meaning that its share price is 185% more volatile than the broader market. Comparatively, Whitehawk Therapeutics has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market.

77.6% of Forte Biosciences shares are held by institutional investors. Comparatively, 52.1% of Whitehawk Therapeutics shares are held by institutional investors. 4.4% of Forte Biosciences shares are held by company insiders. Comparatively, 49.9% of Whitehawk Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Whitehawk Therapeutics has higher revenue and earnings than Forte Biosciences. Forte Biosciences is trading at a lower price-to-earnings ratio than Whitehawk Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forte Biosciences	N/A	N/A	-$69.38M	-$4.64	N/A
Whitehawk Therapeutics	$7.14M	25.69	-$20.60M	-$1.68	N/A

Forte Biosciences currently has a consensus price target of $68.75, suggesting a potential upside of 25.50%. Whitehawk Therapeutics has a consensus price target of $8.20, suggesting a potential upside of 121.02%. Given Whitehawk Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Whitehawk Therapeutics is more favorable than Forte Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forte Biosciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Whitehawk Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Whitehawk Therapeutics' return on equity of -79.63% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forte Biosciences	N/A	-106.17%	-85.50%
Whitehawk Therapeutics	N/A	-79.63%	-74.01%

Summary

Whitehawk Therapeutics beats Forte Biosciences on 11 of the 14 factors compared between the two stocks.

How does Whitehawk Therapeutics compare to Aclaris Therapeutics?

Whitehawk Therapeutics (NASDAQ:WHWK) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Whitehawk Therapeutics has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -832.58%. Aclaris Therapeutics' return on equity of -55.89% beat Whitehawk Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Whitehawk Therapeutics	N/A	-79.63%	-74.01%
Aclaris Therapeutics	-832.58%	-55.89%	-38.49%

52.1% of Whitehawk Therapeutics shares are owned by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are owned by institutional investors. 49.9% of Whitehawk Therapeutics shares are owned by company insiders. Comparatively, 4.8% of Aclaris Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Whitehawk Therapeutics has higher earnings, but lower revenue than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Whitehawk Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Whitehawk Therapeutics	$7.14M	25.69	-$20.60M	-$1.68	N/A
Aclaris Therapeutics	$7.83M	93.29	-$64.92M	-$0.56	N/A

In the previous week, Aclaris Therapeutics had 3 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 5 mentions for Aclaris Therapeutics and 2 mentions for Whitehawk Therapeutics. Whitehawk Therapeutics' average media sentiment score of 1.89 beat Aclaris Therapeutics' score of 1.02 indicating that Whitehawk Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Whitehawk Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Aclaris Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Whitehawk Therapeutics presently has a consensus target price of $8.20, indicating a potential upside of 121.02%. Aclaris Therapeutics has a consensus target price of $11.50, indicating a potential upside of 119.89%. Given Whitehawk Therapeutics' higher possible upside, research analysts plainly believe Whitehawk Therapeutics is more favorable than Aclaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Whitehawk Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

Whitehawk Therapeutics has a beta of 0.77, indicating that its share price is 23% less volatile than the broader market. Comparatively, Aclaris Therapeutics has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market.

Summary

Aclaris Therapeutics beats Whitehawk Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Whitehawk Therapeutics compare to Monopar Therapeutics?

Whitehawk Therapeutics (NASDAQ:WHWK) and Monopar Therapeutics (NASDAQ:MNPR) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

Monopar Therapeutics' return on equity of -12.84% beat Whitehawk Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Whitehawk Therapeutics	N/A	-79.63%	-74.01%
Monopar Therapeutics	N/A	-12.84%	-12.57%

Whitehawk Therapeutics presently has a consensus target price of $8.20, indicating a potential upside of 121.02%. Monopar Therapeutics has a consensus target price of $112.08, indicating a potential upside of 2.01%. Given Whitehawk Therapeutics' higher possible upside, equities research analysts plainly believe Whitehawk Therapeutics is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Whitehawk Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Monopar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07

52.1% of Whitehawk Therapeutics shares are owned by institutional investors. Comparatively, 1.8% of Monopar Therapeutics shares are owned by institutional investors. 49.9% of Whitehawk Therapeutics shares are owned by insiders. Comparatively, 9.7% of Monopar Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Monopar Therapeutics has lower revenue, but higher earnings than Whitehawk Therapeutics. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Whitehawk Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Whitehawk Therapeutics	$7.14M	25.69	-$20.60M	-$1.68	N/A
Monopar Therapeutics	N/A	N/A	-$13.72M	-$1.90	N/A

In the previous week, Monopar Therapeutics had 13 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 15 mentions for Monopar Therapeutics and 2 mentions for Whitehawk Therapeutics. Whitehawk Therapeutics' average media sentiment score of 1.89 beat Monopar Therapeutics' score of 0.92 indicating that Whitehawk Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Whitehawk Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Monopar Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Whitehawk Therapeutics has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market. Comparatively, Monopar Therapeutics has a beta of 1.46, meaning that its stock price is 46% more volatile than the broader market.

Summary

Monopar Therapeutics beats Whitehawk Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Whitehawk Therapeutics compare to Candel Therapeutics?

Candel Therapeutics (NASDAQ:CADL) and Whitehawk Therapeutics (NASDAQ:WHWK) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability, valuation and risk.

Whitehawk Therapeutics has higher revenue and earnings than Candel Therapeutics. Candel Therapeutics is trading at a lower price-to-earnings ratio than Whitehawk Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A
Whitehawk Therapeutics	$7.14M	25.69	-$20.60M	-$1.68	N/A

Candel Therapeutics currently has a consensus price target of $18.57, indicating a potential upside of 94.26%. Whitehawk Therapeutics has a consensus price target of $8.20, indicating a potential upside of 121.02%. Given Whitehawk Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Whitehawk Therapeutics is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Whitehawk Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

13.9% of Candel Therapeutics shares are owned by institutional investors. Comparatively, 52.1% of Whitehawk Therapeutics shares are owned by institutional investors. 14.3% of Candel Therapeutics shares are owned by company insiders. Comparatively, 49.9% of Whitehawk Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Candel Therapeutics' return on equity of -60.42% beat Whitehawk Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Candel Therapeutics	N/A	-60.42%	-41.33%
Whitehawk Therapeutics	N/A	-79.63%	-74.01%

Candel Therapeutics has a beta of -0.52, indicating that its share price is 152% less volatile than the broader market. Comparatively, Whitehawk Therapeutics has a beta of 0.77, indicating that its share price is 23% less volatile than the broader market.

In the previous week, Candel Therapeutics and Candel Therapeutics both had 2 articles in the media. Whitehawk Therapeutics' average media sentiment score of 1.89 beat Candel Therapeutics' score of 0.71 indicating that Whitehawk Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Candel Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Whitehawk Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Whitehawk Therapeutics beats Candel Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Whitehawk Therapeutics compare to Design Therapeutics?

Whitehawk Therapeutics (NASDAQ:WHWK) and Design Therapeutics (NASDAQ:DSGN) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.

Design Therapeutics' return on equity of -33.07% beat Whitehawk Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Whitehawk Therapeutics	N/A	-79.63%	-74.01%
Design Therapeutics	N/A	-33.07%	-31.29%

In the previous week, Whitehawk Therapeutics and Whitehawk Therapeutics both had 2 articles in the media. Whitehawk Therapeutics' average media sentiment score of 1.89 beat Design Therapeutics' score of 0.97 indicating that Whitehawk Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Whitehawk Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Design Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Whitehawk Therapeutics has higher revenue and earnings than Design Therapeutics. Design Therapeutics is trading at a lower price-to-earnings ratio than Whitehawk Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Whitehawk Therapeutics	$7.14M	25.69	-$20.60M	-$1.68	N/A
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A

Whitehawk Therapeutics has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market. Comparatively, Design Therapeutics has a beta of 1.58, meaning that its share price is 58% more volatile than the broader market.

52.1% of Whitehawk Therapeutics shares are owned by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are owned by institutional investors. 49.9% of Whitehawk Therapeutics shares are owned by company insiders. Comparatively, 17.1% of Design Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Whitehawk Therapeutics currently has a consensus target price of $8.20, suggesting a potential upside of 121.02%. Design Therapeutics has a consensus target price of $16.50, suggesting a potential upside of 40.07%. Given Whitehawk Therapeutics' higher probable upside, analysts clearly believe Whitehawk Therapeutics is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Whitehawk Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Design Therapeutics beats Whitehawk Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Whitehawk Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding WHWK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

WHWK vs. The Competition

Export

Metric	Whitehawk Therapeutics	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$189.40M	$966.60M	$7.26B	$12.26B
Dividend Yield	N/A	4.84%	40.99%	9.79%
P/E Ratio	-2.21	1.53	23.62	23.71
Price / Sales	25.69	109.08	173.18	74.83
Price / Cash	N/A	20.06	165.01	59.64
Price / Book	1.28	8.48	12.77	6.07
Net Income	-$20.60M	-$3.23M	$120.21M	$331.84M
7 Day Performance	-4.63%	-2.80%	-0.94%	-1.53%
1 Month Performance	-9.73%	-4.40%	-1.97%	-2.46%
1 Year Performance	90.26%	28.83%	9.83%	13.66%

Whitehawk Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
WHWK Whitehawk Therapeutics	2.453 of 5 stars	$3.71 -3.1%	$8.20 +121.0%	+91.2%	$189.40M	$7.14M	N/A	21	News Coverage
FBRX Forte Biosciences	2.3837 of 5 stars	$59.70 +5.4%	$68.75 +15.2%	+409.6%	$786.34M	N/A	N/A	5	News Coverage Analyst Forecast
ACRS Aclaris Therapeutics	2.9894 of 5 stars	$5.48 -2.5%	$11.50 +109.9%	+211.3%	$784.91M	$7.83M	N/A	100	News Coverage
MNPR Monopar Therapeutics	1.6455 of 5 stars	$105.70 -6.0%	$112.08 +6.0%	+134.7%	$753.51M	N/A	N/A	10	News Coverage Analyst Forecast Analyst Revision
CADL Candel Therapeutics	2.8756 of 5 stars	$9.86 -2.3%	$18.57 +88.4%	+36.6%	$739.30M	N/A	N/A	60	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:WHWK) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Whitehawk Therapeutics (WHWK) Competitors

WHWK vs. FBRX, ACRS, MNPR, CADL, and DSGN

How does Whitehawk Therapeutics compare to Forte Biosciences?

Summary

How does Whitehawk Therapeutics compare to Aclaris Therapeutics?

Summary

How does Whitehawk Therapeutics compare to Monopar Therapeutics?

Summary

How does Whitehawk Therapeutics compare to Candel Therapeutics?

Summary

How does Whitehawk Therapeutics compare to Design Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

WHWK vs. The Competition

Whitehawk Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Whitehawk Therapeutics (WHWK) Competitors

WHWK vs. FBRX, ACRS, MNPR, CADL, and DSGN

How does Whitehawk Therapeutics compare to Forte Biosciences?

Does the media favor FBRX or WHWK?

Which has more volatility and risk, FBRX or WHWK?

Do insiders & institutionals hold more shares of FBRX or WHWK?

Which has better valuation and earnings, FBRX or WHWK?

Do analysts rate FBRX or WHWK?

Is FBRX or WHWK more profitable?

Summary

How does Whitehawk Therapeutics compare to Aclaris Therapeutics?

Is WHWK or ACRS more profitable?

Do insiders and institutionals have more ownership in WHWK or ACRS?

Which has better valuation and earnings, WHWK or ACRS?

Does the media prefer WHWK or ACRS?

Do analysts rate WHWK or ACRS?

Which has more volatility & risk, WHWK or ACRS?

Summary

How does Whitehawk Therapeutics compare to Monopar Therapeutics?

Is WHWK or MNPR more profitable?

Do analysts rate WHWK or MNPR?

Do insiders & institutionals believe in WHWK or MNPR?

Which has stronger earnings & valuation, WHWK or MNPR?

Does the media refer more to WHWK or MNPR?

Which has more volatility and risk, WHWK or MNPR?

Summary

How does Whitehawk Therapeutics compare to Candel Therapeutics?

Which has stronger valuation and earnings, CADL or WHWK?

Do analysts prefer CADL or WHWK?

Do insiders and institutionals believe in CADL or WHWK?

Is CADL or WHWK more profitable?

Which has more risk and volatility, CADL or WHWK?

Does the media favor CADL or WHWK?

Summary

How does Whitehawk Therapeutics compare to Design Therapeutics?

Is WHWK or DSGN more profitable?

Does the media prefer WHWK or DSGN?

Which has stronger valuation and earnings, WHWK or DSGN?

Which has more risk & volatility, WHWK or DSGN?

Do insiders & institutionals hold more shares of WHWK or DSGN?

Do analysts prefer WHWK or DSGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

WHWK vs. The Competition

Whitehawk Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools